Key Highlights

  • Shares are trading up 5.10% intraday to $2.06, from a prior close of $1.96
  • Announced completion of its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
  • All clinical data collection across the company's FDA 510(k) clinical study program is now complete
  • Study enrolled 135 participants across three independent U.S. clinical sites over three weeks
  • Study conducted in Partnership with CenExel Clinical Research following ICH GCP guidelines
  • FDA submission remains on track for the second half of 2026
  • Market Capitalization stands at $1.33 million, with a 52-week range of $1.52 to $24.90

Shares Rise on Completion of Key Clinical Study

Intelligent Bio Solutions (NASDAQ:INBS) shares are trading up 5.10% intraday to $2.06, from a prior close of $1.96. The move follows the company's announcement that it has completed its multi-site Method Comparison Study for the Intelligent Fingerprinting Drug Screening System, one of several studies underpinning its FDA 510(k) submission for detection of the opiate codeine.

The completion marks a milestone for the company, as all clinical data collection across its FDA 510(k) clinical study program is now complete. The study enrolled 135 participants across three independent U.S. clinical sites over three weeks, with the population structured to represent the demographic diversity of the U.S. population, conducted in partnership with CenExel Clinical Research following International Council for Harmonisation Good Clinical Practice guidelines.

What Intelligent Bio Solutions Does

Intelligent Bio Solutions is a New York-based medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions across global markets. The company's flagship product, the Intelligent Fingerprinting Drug Screening System, aims to revolutionize portable testing through fingerprint sweat analysis, detecting substances such as opiates, cocaine, methamphetamine, and cannabis, delivering results in under ten minutes across safety-critical industries including construction, mining, transport, and logistics.

The technology is designed as a hygienic and cost-effective system, with sample collection in seconds, offering a valuable tool for employers in safety-critical industries. The company's solutions currently sell in 35 countries and territories, and Intelligent Bio Solutions is led by President and Chief Executive Officer Harry Simeonidis.

Study Design and Path to FDA Submission

The Method Comparison Study was designed to demonstrate that typical users in occupational health, human resources, and workplace safety roles can operate the Intelligent Fingerprinting Drug Screening System accurately and effectively in the field. The screening process was administered by nine operator participants representing typical workplace drug screening personnel, evaluating sensitivity, specificity, and accuracy in pre-employment and workplace screening environments.

President and Chief Executive Officer Harry Simeonidis said completing this final study on schedule is the milestone the entire program has been building toward, calling it a substantial body of clinical evidence. The company is now in the final stretch of data analysis and assembly of its FDA 510(k) submission package, with all specimens to be independently verified via liquid chromatography-tandem mass spectrometry analysis, targeting submission in the second half of 2026 ahead of planned entry into the multi-billion-dollar U.S. market.

Conclusion

Intelligent Bio Solutions' intraday gain reflects investor recognition of a meaningful regulatory milestone, with the completion of clinical data collection marking the conclusion of a structured, multi-study program addressing safety, accuracy, usability, specificity, and precision requirements for its drug screening technology. With the company now focused on finalizing its FDA 510(k) submission package targeted for the second half of 2026, the stock's reaction suggests investors view the completed study as a meaningful step toward the company's planned entry into the U.S. workplace drug screening market.